Canaccord raised the firm’s price target on TransMedics to $117 from $102 and keeps a Buy rating on the shares. The firm said management also called for sustained profitability and of note was the company’s commentary on working on a cold perfusion product for heart to address the standard DBD Heart market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: